Glanbia (GLAPY) Stock Rating Lowered by Zacks Investment Research

Share on StockTwits

Glanbia (OTCMKTS:GLAPY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Glanbia Plc engages in the manufacture and distribution of dairy and nutritional food products. Its operating segments include Glanbia Performance Nutrition, Global Ingredients, Dairy Ireland and Joint Ventures and Associates. Glanbia Performance Nutrition segment comprises of performance nutrition products under the Optimum Nutrition, BSN, Isopure, Nutramino and ABB brands. Global Ingredients segment includes American-style cheddar cheese, micro-nutrient premixes and dairy and non-dairy nutritional solutions. Dairy Ireland segment consists of consumer products and agribusiness. Joint Ventures and Associates segment covers Glanbia Ingredients Ireland, Glanbia Cheese and Southwest Cheese. Glanbia Plc is headquartered in Kilkenny, Ireland. “

OTCMKTS:GLAPY remained flat at $$86.81 during trading hours on Wednesday. Glanbia has a 1-year low of $80.23 and a 1-year high of $98.16. The firm has a market cap of $5.14 billion, a P/E ratio of 17.22, a PEG ratio of 4.52 and a beta of 0.01.

About Glanbia

Glanbia plc operates as a nutrition company worldwide. It operates through three segments: Glanbia Performance Nutrition, Glanbia Nutritionals, and Glanbia Ireland Joint Venture. The Glanbia Performance Nutrition segment offers powders, bars and snacking food, and ready-to-drink beverages through various channels, including specialty retail, the Internet, and gyms, as well as food, drug, mass, and club channels.

Featured Article: 52-Week High/Low Prices For Stock Selection

Get a free copy of the Zacks research report on Glanbia (GLAPY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Glanbia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glanbia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply